再生醫學領域的合作與授權協議（2019-2026 年）

Regenerative Medicine Collaboration and Licensing Deals 2019-2026

出版日期: 2026年05月01日 | 出版商:

Current Partnering | 英文 800+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

再生醫學領域交易的權威基準

再生醫學領域的合作是由旨在恢復、替代和再生生物功能的治療方法所驅動的，其合約結構反映了細胞療法、再生醫學和組織工程方法的融合。

本報告對再生醫學領域 1500 多項合作與許可協議進行了全面系統的分析，清楚地展示了整個市場夥伴關係的設計、談判和執行方式，並以證據為基礎進行了闡述。

清楚了解市場標準

本報告對再生醫學領域的合約實際構成方式進行了精確闡述。

類似交易的可靠基準
對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
定義切合實際的市場參數
清楚洞察基於治療方法類型、開發階段和合作夥伴情況的合約條款差異。
支持基於證據的評估和合約結構確定。
讓內部討論基於實際交易數據，而不是僅基於假設。
了解主要公司的交易方式
在高度創新和跨學科的治療領域中，可視化合作夥伴的行為模式和反覆出現的合約結構。
完全透明地了解合約的結構和執行情況
本報告超越了表面的合約數據，提供了對底層合約文件的訪問，以便詳細了解實際協議是如何構建的。

這包括以下內容：

授予和保留的權利
負責開發和商業化
財務結構和付款條款
關鍵合約條款和保護措施
這種透明度對於理解再生醫學領域合作中價值、風險和控制權的分配至關重要。在應對漫長的研發週期和複雜的生產需求時，其重要性就更加凸顯。
專為實際業務發展和策略應用而設計。

本報告廣泛用於以下用途：

設計和評估先進醫學和再生醫學領域的交易。
在清晰的市場環境下準備談判
對許可、合作開發和平台合作關係進行評估。
利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

在再生醫學領域達成了超過 1500 項合作與許可協議。
財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
可全文搜尋的合約目錄（按公司、技術和應用）
可直接查閱向美國證券交易委員會提交的合約和原始文件。
合約趨勢、重大交易和活躍合約方分析。
再生醫學領域交易中可靠的依證。
本報告結合了全面的合約資料涵蓋和詳細的合約層面分析，為在再生醫學領域建立、談判和評估夥伴關係提供了可靠的、依證的資源。

合約目錄
合約目錄：再生醫學合約（依公司 A-Z 排序）
合約目錄：依合約類型分類的再生醫學合約
合約目錄：按治療領域分類的再生醫學合約
合約類型的定義
關於 Biopharma Research Ltd.
關於當前合作夥伴關係
關於現行協議
Current Partnering 最新報告列表

簡介目錄

Product Code: CP2116

The definitive benchmark for regenerative medicine dealmaking

Regenerative medicine partnering is driven by therapies designed to restore, replace, or regenerate biological function, with deal structures reflecting the convergence of cell therapy, gene therapy, and tissue engineering approaches.

This report provides a comprehensive and structured analysis of 1500+ regenerative medicine collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how regenerative medicine deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by technology type, therapeutic application, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a highly innovative and cross-disciplinary therapeutic landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within regenerative medicine partnerships, particularly where long development timelines and complex manufacturing requirements are involved.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark advanced therapy and regenerative transactions
Prepare for negotiations with well-defined market context
Evaluate licensing, co-development, and platform partnerships
Support internal strategy with robust, defensible data
What's included
1500+ regenerative medicine collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, technology, and application)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for regenerative medicine dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how regenerative medicine partnerships are structured, negotiated, and valued.

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in regenerative medicine dealmaking

2.1. Introduction
2.2. Regenerative medicine deals over the years
2.3. Most active regenerative medicine dealmakers
2.4. Regenerative medicine deals by deal type
2.5. Regenerative medicine deals by therapy area
2.6. Regenerative medicine deals by industry sector
2.7. Deal terms for regenerative medicine deals
- 2.7.1 Regenerative medicine deals headline values
- 2.7.2 Regenerative medicine deal upfront payments
- 2.7.3 Regenerative medicine deal milestone payments
- 2.7.4 Regenerative medicine royalty rates